Integrated microfluidic device for the direct analysis of drugs and metabolites in biological fluids

用于直接分析生物体液中药物和代谢物的集成微流体装置

• 批准号: DP0984745
• 负责人: Prof Michael Breadmore
• 金额: $ 50.34万
• 依托单位: University of Tasmania
• 依托单位国家: 澳大利亚
• 项目类别: Discovery Projects
• 财政年份: 2009
• 资助国家: 澳大利亚
• 起止时间: 2009-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/DP0984745
• 关键词: Integrated; microfluidic; device; direct; analysis

Due to the way in which multiple processes are integrated in a micro Total Analysis System (µTAS), they offer substantial advantages over current technology, in terms of speed, cost of analysis, portability and operator simplicity and safety. This has considerable potential benefit for Australia, specifically for the remote and rural analysis of drugs and metabolites in biological fluids such as blood, serum, urine and saliva. These devices will have application for point-of-care testing in therapeutic drug monitoring, which will improve medical treatment and the patient's quality of life, as well as for on-site analysis in forensics for the rapid determination of illicit drugs and performance enhancing substances in our elite athletes.

由于多个过程集成在一个微型全分析系统（µTAS）中的方式，它们在速度，分析成本，可移植性以及操作简单性和安全性方面比当前技术具有实质性优势。这对澳大利亚具有相当大的潜在好处，特别是对血液、血清、尿液和唾液等生物液体中的药物和代谢物进行远程和农村分析。这些装置将用于治疗性药物监测中的护理点测试，这将改善医疗和患者的生活质量，并用于法医现场分析，以便快速确定我国优秀运动员服用的非法药物和提高成绩的物质。